#1 Clinical Trials Search in Europe

Humanised Igg1K Monoclonal Antibody Against Interferon Beta

Recent clinical trials are investigating the use of a Humanised IgG1K Monoclonal Antibody Against Interferon Beta, also known as Dazukibart or PF-06823859, for treating various autoimmune conditions. These studies aim to evaluate the drug’s effectiveness and safety in patients with idiopathic inflammatory myopathies, cutaneous lupus erythematosus, and systemic lupus erythematosus with skin symptoms. The trials are designed to assess the drug’s impact on reducing muscle and skin symptoms, as well as its overall effect on patients’ health status.

Table of Contents

What is Dazukibart?

Dazukibart, also known as PF-06823859, is a new medication being developed to treat certain autoimmune conditions[1]. It is a type of drug called a humanized IgG1K monoclonal antibody. This means it’s a specially designed protein that can target specific parts of the immune system[2].

How Does Dazukibart Work?

Dazukibart works by targeting a substance in your body called interferon beta. Interferon beta is a protein that plays a role in inflammation and immune responses. In some autoimmune conditions, there might be too much interferon beta activity, which can lead to harmful inflammation. Dazukibart is designed to block or neutralize interferon beta, potentially reducing inflammation and helping to control the overactive immune response[1][2].

Conditions Treated

Dazukibart is being studied for several autoimmune conditions, including:

  • Idiopathic Inflammatory Myopathies (IIM): This includes conditions like dermatomyositis (DM) and polymyositis (PM), which cause muscle inflammation and weakness[1].
  • Cutaneous Lupus Erythematosus (CLE): A condition that primarily affects the skin, causing rashes and lesions[2].
  • Systemic Lupus Erythematosus (SLE) with skin symptoms: A more widespread form of lupus that can affect multiple organs, including the skin[2].

Clinical Trials

Dazukibart is currently being tested in clinical trials to determine its effectiveness and safety. Two important studies are:

  1. A Phase 3 study for idiopathic inflammatory myopathies (including dermatomyositis and polymyositis)[1].
  2. A Phase 2 study for cutaneous lupus erythematosus and systemic lupus erythematosus with skin symptoms[2].

These trials are designed to evaluate how well Dazukibart works compared to a placebo (a treatment with no active ingredients) and to assess its safety profile.

Administration and Dosage

Dazukibart is given as an intravenous (IV) injection, which means it’s administered directly into a vein[1][2]. The exact dosage and frequency of administration are still being determined through clinical trials, but current studies are testing doses up to 600 mg per day[1][2].

Potential Benefits

Researchers hope that Dazukibart may offer several benefits for patients with autoimmune conditions:

  • Reduction in muscle symptoms for patients with dermatomyositis and polymyositis[1].
  • Improvement in skin symptoms for patients with lupus skin involvement[2].
  • Potential improvement in overall disease activity and patient health status[1][2].

Safety and Side Effects

As Dazukibart is still in clinical trials, its full safety profile is not yet known. The ongoing studies are carefully monitoring for any side effects or safety concerns. Patients in the trials are being closely watched for:

  • Changes in laboratory test results
  • Changes in vital signs
  • Abnormalities in heart rhythm (ECG changes)
  • Any adverse events or serious adverse events[2]

It’s important to note that all medications can have side effects, and the benefits and risks should be carefully considered with your healthcare provider.

Ongoing Research

Research on Dazukibart is ongoing, and scientists are continuing to learn more about its effects and potential uses. Future studies may explore its use in other autoimmune conditions or investigate long-term effects and optimal dosing strategies.

If you’re interested in learning more about Dazukibart or participating in clinical trials, it’s important to discuss this with your healthcare provider. They can provide more information and help determine if this treatment might be appropriate for your specific situation.

Aspect Details
Drug Name Humanised IgG1K Monoclonal Antibody Against Interferon Beta (Dazukibart, PF-06823859)
Conditions Studied Idiopathic Inflammatory Myopathies (Dermatomyositis, Polymyositis), Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus with skin symptoms
Administration Intravenous injection
Trial Phases Phase 2 and Phase 3
Primary Objectives Evaluate efficacy in reducing muscle and skin symptoms, assess safety and tolerability
Key Measurements CLASI-A score, type 1 IFN gene signature score, muscle strength tests, patient-reported outcomes
Eligibility (general) Adults with active disease forms, meeting specific criteria for disease severity and current treatments
Treatment Duration Varies by study, up to 52 weeks

FAQ

  • What is Humanised IgG1K Monoclonal Antibody Against Interferon Beta? It's a type of medication being studied for autoimmune conditions. It's also known as Dazukibart or PF-06823859. This antibody targets a specific part of the immune system involved in these diseases.
  • What conditions are being studied with this drug? The drug is being tested for idiopathic inflammatory myopathies (including dermatomyositis and polymyositis), cutaneous lupus erythematosus (CLE), and systemic lupus erythematosus (SLE) with skin symptoms.
  • How is the drug administered? The drug is given as an intravenous (IV) injection, which means it's delivered directly into the bloodstream through a vein.
  • What are the main goals of these clinical trials? The trials aim to evaluate the drug's effectiveness in reducing muscle and skin symptoms, assess its safety, and measure its impact on patients' overall health status compared to a placebo.
  • Who can participate in these trials? Generally, adult patients (18 years or older) with active forms of the studied conditions who meet specific criteria regarding disease severity and current treatments. However, there are numerous inclusion and exclusion criteria that determine eligibility.

Ongoing Clinical Trials on Humanised Igg1K Monoclonal Antibody Against Interferon Beta

  • Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +4

  • Study of PF-06823859 for Adults with Active Cutaneous or Systemic Lupus Erythematosus with Skin Symptoms

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Greece Spain

Glossary

  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. It's designed to target specific parts of the immune system or other cells.
  • Idiopathic Inflammatory Myopathies (IIM): A group of rare muscle diseases characterized by muscle inflammation and weakness. 'Idiopathic' means the cause is unknown.
  • Dermatomyositis (DM): A type of inflammatory myopathy that affects the skin and muscles, causing muscle weakness and a distinctive skin rash.
  • Polymyositis (PM): An inflammatory muscle disease causing muscle weakness, usually affecting muscles close to the trunk of the body.
  • Cutaneous Lupus Erythematosus (CLE): A form of lupus that primarily affects the skin, causing rashes and lesions.
  • Systemic Lupus Erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • Placebo: A substance that has no active ingredients and is used as a control in testing new drugs.
  • CLASI-A: Cutaneous Lupus Erythematosus Disease Area and Severity Index – Activity, a tool used to measure the severity of skin symptoms in lupus.
  • Interferon Beta: A type of protein naturally produced by the body that plays a role in immune responses. In some autoimmune conditions, it may contribute to inflammation.
  • Immunosuppressant: A type of drug that reduces the strength of the body's immune system.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-dazukibart-in-adults-with-active-dermatomyositis-or-polymyositis/
  2. http://clinicaltrials.eu/trial/study-of-pf-06823859-for-adults-with-active-cutaneous-or-systemic-lupus-erythematosus-with-skin-symptoms/